GleamWall
中文EN

GMED GLOBUS MEDICAL INC

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1237831 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.4%
TTM net income YoY31.6%
TTM EPS YoY31.4%
Revenue 3-yr CAGR36.8%
Net income 3-yr CAGR52.3%

Margins

Gross margin69.1%
Operating margin21.6%
Net margin17.8%
FCF margin24.4%
EBITDA margin28.7%

Returns

ROE12.1%
ROA10.5%
ROIC (approx.)12.9%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets13.2%
Debt / equity0.00x
Current ratio4.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue5.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$763.72M$789.61M$759.85M$826.42M$769.05M$745.34M$598.12M$657.29M
Cost of revenue$232.92M$241.44M$234.07M$261.11M$252.53M$248.76M$195.40M$263.44M
Gross profit$530.80M$548.17M$525.79M$565.31M$516.51M$496.58M$402.72M$393.86M
R&D expense$34.53M$36.32M$36.51M$36.16M$38.07M$39.95M$33.06M$33.41M
SG&A expense$288.47M$286.82M$297.77M$318.48M$313.60M$303.62M$242.80M$253.17M
Operating income$177.55M$182.43M$150.39M$169.34M$137.36M$76.11M$97.00M$60.27M
Pretax income$183.27M$189.82M$157.07M$169.23M$143.99M$188.17M$103.67M$24.67M
Income tax$42.10M$38.25M$32.77M$28.64M$25.03M-$14.67M$28.21M-$1.84M
Net income$141.17M$151.57M$124.30M$140.59M$118.97M$202.85M$75.46M$26.50M
EBITDA$218.91M$222.96M$220.24M$238.82M$178.65M$116.55M$162.66M$127.87M
EPS (basic)1.051.120.92—0.881.500.55—
EPS (diluted)1.041.100.90—0.881.490.54—
Weighted avg. shares (diluted)136.02M137.38M138.19M—135.39M136.50M139.77M—
Banking
Net interest income————$1.46M$693,000$1.68M$815,000
Balance sheet
Cash & equivalents$441.27M$507.75M$560.95M$526.16M$371.77M$229.45M$461.27M$784.44M
Short-term investments$76.16M$87.40M$68.90M$31.09M$18.75M——$105.62M
Receivables$675.30M$692.18M$686.43M$678.94M$619.12M$611.57M$535.09M$557.70M
Inventory$824.14M$810.90M$772.60M$759.28M$771.54M$772.13M$663.60M$659.23M
Current assets$2.18B$2.22B$2.20B$2.13B$1.92B$1.73B$1.71B$2.18B
PP&E, net$532.76M$533.53M$557.14M$564.45M$577.79M$587.50M$556.50M$561.91M
Goodwill$1.45B$1.44B$1.44B$1.44B$1.43B$1.43B$1.43B$1.43B
Intangibles$667.47M$692.62M$720.85M$745.06M$773.90M$796.37M$771.69M$795.12M
Total assets$5.53B$5.49B$5.44B$5.30B$5.10B$4.96B$4.71B$5.25B
Current liabilities$507.94M$479.35M$482.46M$498.50M$465.96M$424.66M$384.70M$855.91M
Total liabilities$731.94M$719.65M$707.24M$729.51M$696.82M$665.41M$623.08M$1.07B
Shareholders' equity$4.80B$4.77B$4.73B$4.57B$4.40B$4.30B$4.09B$4.18B
Cash flow statement
Operating cash flow$265.23M$209.74M$202.36M$248.59M$249.69M$77.86M$177.30M$210.34M
Capital expenditure$40.39M$33.17M$39.62M$46.20M$35.82M$46.56M$36.10M$17.11M
Free cash flow$224.84M$176.57M$162.75M$202.39M$213.88M$31.30M$141.20M$193.23M
Investing cash flow-$155.90M-$129.05M-$182.67M-$111.45M-$75.84M-$299.11M$131.38M-$104.12M
Financing cash flow-$130.76M-$134.50M$18.20M$13.21M-$32.04M-$24.94M-$635.40M$59.73M
Depreciation & amortization$41.36M$40.52M$69.86M$69.48M$41.28M$40.44M$65.65M$67.59M
Stock-based compensation$11.74M$13.38M$12.62M$11.42M$11.54M$13.62M$13.21M$11.91M
Share buybacks$142.94M$136.06M$0$45.00M$40.00M$25.00M$190.45M$1.00M

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.